Medical Affairs is uniquely positioned as the only department capable of impacting the Enterprise Commercialization Process (ECP) at every stage, from the initial product concept through the entire commercialization effort.
This article explores how Sumitomo Pharma America (SMPA) leveraged H1’s advanced data capabilities to integrate diverse insights, enhance field medical strategies, and foster cross-functional collaboration across therapeutic areas.
This article explores key questions on how Medical Affairs teams manage patient engagement across different-sized companies who have variations in focus, resources, and scale.
This article based on the Oct 3, 2024 Insights FAWG Forum explores the potential for artificial intelligence (AI) to transform Medical Affairs, focusing on medical insights.
Medical Affairs is in the unique position to drive health equity through three main roles: catalyser, capabilities enhancer, and cross-functional collaborator, emphasizing the need for deliberate strategies and actions to close health gaps and improve outcomes for underserved populations.
Continuing Medical Education (CME) providers have seen their role expand to offer valuable information for future programming and other strategic business decisions. Here is how CME providers are using data to create insights and impact.
The MAPS Puerto Rico Roundtable hosted by Real Chemistry in March 2024 discussed the integration of digital platforms, AI, and personalized content to enhance engagement with healthcare providers (HCPs). The panel emphasized the shift towards real-time, tailored information delivery and the importance of leveraging insights from both traditional and digital sources to support effective engagement strategies while ensuring compliance.
Drawing on insights from a roundtable of industry leaders convened by Klick at the recent MAPS conference, let’s look at how viewing the KOL holistically can lead to new avenues of engagement and more multifaceted relationships.
Addressing the critical importance of integrating robust scientific understanding into the commercial journey, pinpointing the need for medical affairs to take the helm in defining and communicating the commercial value of healthcare innovations.
From the choice of where to publish to the assessment of impact, every decision holds weight in medical research publication. And yet, the metrics that have been traditionally used to guide these decisions offer only a partial view. The result: a hit-or-miss situation when it comes to reaching the target audience—healthcare professionals (HCPs) and patients. Can a data-driven approach that incorporates both traditional and the newer alternative metrics hold the key to improved publication planning, impact and thereby better patient outcomes?